Current Challenges and Practical Aspects of Molecular Pathology for Bone and Soft Tissue Tumors

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2024 Jan 16

PMID 38228904

Authors

Enrique de Alava

Affiliations

Soon will be listed here.

Abstract

This review shows the extraordinary change molecular pathology has induced in the classification, diagnosis, and clinical practice of molecular pathologists dealing with sarcomas. We have primarily focused on the practical aspects of molecular studies and the current and mid-term challenges for our subspecialty, ending with ten tips for the next generation of sarcoma molecular pathologists.

References

Flaherty K, Gray R, Chen A, Li S, Patton D, Hamilton S . The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020; 112(10):1021-1029. PMC: 7566320. DOI: 10.1093/jnci/djz245. View

Lanzi C, Bo L, Favini E, Tortoreto M, Beretta G, Arrighetti N . Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma. Cancers (Basel). 2019; 11(3). PMC: 6468361. DOI: 10.3390/cancers11030408. View

Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss D . Sarcoma classification by DNA methylation profiling. Nat Commun. 2021; 12(1):498. PMC: 7819999. DOI: 10.1038/s41467-020-20603-4. View

Martin S, Clark S, Gerrand C, Gilchrist K, Lawal M, Maio L . Patients' Experiences of a Sarcoma Diagnosis: A Process Mapping Exercise of Diagnostic Pathways. Cancers (Basel). 2023; 15(15). PMC: 10417695. DOI: 10.3390/cancers15153946. View

Wang L, Zehir A, Sadowska J, Zhou N, Rosenblum M, Busam K . Consistent copy number changes and recurrent PRKAR1A mutations distinguish Melanotic Schwannomas from Melanomas: SNP-array and next generation sequencing analysis. Genes Chromosomes Cancer. 2015; 54(8):463-471. PMC: 6446921. DOI: 10.1002/gcc.22254. View

Baumhoer D, Amary F, Flanagan A . An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes Cancer. 2018; 58(2):88-99. DOI: 10.1002/gcc.22699. View

Lam S, Silva T, Bovee J . New molecular entities of soft tissue and bone tumors. Curr Opin Oncol. 2022; 34(4):354-361. DOI: 10.1097/CCO.0000000000000844. View

Kallen M, Hornick J . The 2020 WHO Classification: What's New in Soft Tissue Tumor Pathology?. Am J Surg Pathol. 2020; 45(1):e1-e23. DOI: 10.1097/PAS.0000000000001552. View

Marcilla D, Machado I, Grunewald T, Llombart-Bosch A, de Alava E . (Immuno)histological Analysis of Ewing Sarcoma. Methods Mol Biol. 2020; 2226:49-64. DOI: 10.1007/978-1-0716-1020-6_5. View

10.

Wen X, Cimera R, Aryeequaye R, Abhinta M, Athanasian E, Healey J . Recurrent loss of chromosome 22 and SMARCB1 deletion in extra-axial chordoma: A clinicopathological and molecular analysis. Genes Chromosomes Cancer. 2021; 60(12):796-807. PMC: 8511200. DOI: 10.1002/gcc.22992. View

11.

Cardoso E, Guidi M, Blanchet B, Schneider M, Decosterd L, Buclin T . Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Ther Drug Monit. 2019; 42(1):33-44. DOI: 10.1097/FTD.0000000000000699. View

12.

Cordier F, Creytens D . New kids on the block: and gene. J Clin Pathol. 2023; 76(11):721-726. DOI: 10.1136/jcp-2023-208931. View

13.

Chen C, Chang K, Chuang C, Fu J, Huang H . The emerging PRRX1-NCOA fibroblastic neoplasm: a combined reappraisal of published tumors and two new cases. Virchows Arch. 2021; 481(1):111-116. DOI: 10.1007/s00428-021-03219-x. View

14.

Peron J, Marreaud S, Staelens D, Raveloarivahy T, Nzokirantevye A, Flament J . A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial. Eur J Cancer. 2019; 109:192-195. DOI: 10.1016/j.ejca.2018.12.013. View

15.

Estupinan O, Rey V, Tornin J, Murillo D, Gallego B, Huergo C . Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling. Biomed Pharmacother. 2023; 162:114627. DOI: 10.1016/j.biopha.2023.114627. View

16.

Berclaz L, Burkhard-Meier A, Lange P, Di Gioia D, Schmidt M, Knosel T . Implementing precision oncology for sarcoma patients: the CCCmolecular tumor board experience. J Cancer Res Clin Oncol. 2023; 149(15):13973-13983. PMC: 10590320. DOI: 10.1007/s00432-023-05179-y. View

17.

Liu Y, Wang W, Yeh J, Wu Y, Mantilla J, Fletcher C . Calcified chondroid mesenchymal neoplasms with FN1-receptor tyrosine kinase gene fusions including FGFR2, FGFR1, MERTK, NTRK1, and TEK: a molecular and clinicopathologic analysis. Mod Pathol. 2021; 34(7):1373-1383. DOI: 10.1038/s41379-021-00786-x. View

18.

Chang K, Goytain A, Tucker T, Karsan A, Lee C, Nielsen T . Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform. J Mol Diagn. 2017; 20(1):63-77. DOI: 10.1016/j.jmoldx.2017.09.007. View

19.

Casali P, Abecassis N, Aro H, Bauer S, Biagini R, Bielack S . Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv68-iv78. DOI: 10.1093/annonc/mdy095. View

20.

Demetri G, Antonescu C, Bjerkehagen B, Bovee J, Boye K, Chacon M . Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020; 31(11):1506-1517. PMC: 7985805. DOI: 10.1016/j.annonc.2020.08.2232. View